Apogee Therapeutics, Inc.
APGEApogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized biologics for major inflammatory and immunology (I&I) markets.
Earnings
Next report
Aug 10, 2026 (In 1 week)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
Profile
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized biologics for major inflammatory and immunology (I&I) markets. The company utilizes advanced antibody engineering to enhance the half-life and efficacy of therapies targeting well-established biological mechanisms. Their primary goal is to provide differentiated dosing and improved clinical outcomes for patients with conditions such as atopic dermatitis, asthma, and COPD.
Apogee positions itself as a developer of best-in-class biologics by optimizing half-life and dosing schedules compared to existing standard-of-care therapies.
Questions, answered.
- What is Apogee Therapeutics, Inc.'s market cap?
- Apogee Therapeutics, Inc. (APGE) has a market capitalization of $10.2B and trades on NASDAQ.
- Who are Apogee Therapeutics, Inc.'s competitors?
- Apogee Therapeutics, Inc.'s key competitors include Regeneron Pharmaceuticals, Eli Lilly and Company, AbbVie, and others. These companies compete in similar markets and product categories.
- Where is Apogee Therapeutics, Inc. headquartered?
- Apogee Therapeutics, Inc. is headquartered in United States of America and employs approximately 91 people. It has been publicly traded since 2023.